DiaMedica Therapeutics Inc.
DMACDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
How DMAC's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Recombinant human tissue kallikrein | Phase 3 | Acute Stroke | - | - |
DM199 | Phase 2 | Kidney Diseases | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in DiaMedica Therapeutics Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in DiaMedica Therapeutics Inc.'s (DMAC) pipeline across Phase 3, Phase 2. Its lead program is Recombinant human tissue kallikrein (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is DiaMedica Therapeutics Inc.'s next FDA catalyst?→
DiaMedica Therapeutics Inc.'s (DMAC) next tracked catalyst is a Phase 3 expected December 15, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track DMAC biotech catalysts?→
Add DMAC to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow DiaMedica Therapeutics Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.